Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA CART123 in Relapsed or Refractory AML
NCT02623582Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Anti-CD123-CAR-transduced T cells in acute myeloid leukemia (AML) (2 cohorts), sponsored by University of Pennsylvania. Primary endpoint: Number of Adverse Events at 2 years. Started Dec 2015; status: terminated.
02
Drugs
Anti-CD123-CAR-transduced T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02623582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623582.